CULVER CITY, CA – April 23, 2018 – Indi Molecular and Caltech today announced a paper published in Angewandte Chemie International Edition on a targeted PCC that modulates the folding of SOD1, a protein implicated in amyotrophic lateral sclerosis.
Read MoreCULVER CITY, CA – January 16, 2018 – Indi Molecular today announced that it has published preclinical research data on a Novel IL-17F therapeutic macrocyclic peptide in Chemistry – A European Journal.
Read MoreCULVER CITY, CA – December 20, 2017 – Indi Molecular, an emerging life sciences company, announced today that it has appointed Stephen Worsley as senior vice president business development.
Read MoreNext-Generation Antibodies and Protein Analysis (2nd Edition): VIB Tools & Technologies Conference
16-17 October 2017 | Ghent, Belgium
Dr. Heather Agnew | Speaker
Chemical & Engineering News (June 30, 2017)
Indi Molecular has secured $11.5 million in Series A funding to support the development of small peptides that act like antibodies.
360Dx / GenomeWeb (June 30, 2017)
Indi Molecular said this week it has closed an $11.5 million Series A financing round led by Merck Ventures, Legend Capital, Sabey Corp
BioCentury (June 29, 2017)
Read MoreBioWorld Medtech (June 29, 2017)
Read MoreCULVER CITY, CA – June 28, 2017 – Indi Molecular, an emerging life sciences company that is developing a novel, synthetic class of binders with antibody-like properties called protein catalyzed capture agents (PCCs), announced today that it has raised a $11.5 million Series-A financing led by M Ventures (Merck Ventures BV, Amsterdam, the Netherlands, a subsidiary of Merck KGaA, Darmstadt Germany known as M Ventures in the United States and Canada), the strategic corporate venture capital arm of Merck KGaA Darmstadt, Germany; Legend Capital, a venture capital/private equity fund based in Beijing; Sabey Corporation; and existing investors including Asset Management Ventures. As part of the financing, Dr. Andreas Jurgeit from Merck Ventures and Dr. Darren Cai from Legend Capital will join Indi Molecular’s board. The Series-A proceeds will be used to establish a high throughput PCC discovery platform and to advance existing leads in PET immuno-oncology imaging to clinical stage.
Read MoreAngewandte Chemie (April 29, 2015)
Read MoreCULVER CITY, CA – (April 13, 2015) – Researchers at Caltech and Indi Molecular announced today a landmark publication in Nature Chemistry suggesting that the PCC (protein catalyzed capture) agent binding technology may enable the creation of highly specific therapeutics for targets that have long been considered undruggable. PCC technology was invented at Caltech and is being commercialized by Indi Molecular.
Read MoreGenomeWeb | Dec 19, 2014 | Adam Bonislawski
“As we have talked to pharmaceutical companies, it has become very clear that their interest is in super-binding molecules that can target very low abundance therapeutic targets, things that are really hard to reach with a monoclonal,” said
Press Release | 17 December 2014
CULVER CITY, CA — Indi Molecular, the maker of a synthetic replacement for monoclonal antibodies, today announced that it has entered into a co-development agreement with Sigma-Aldrich to explore the use of Indi Molecular’s PCC technology with Sigma-Aldrich’s line of biological tools. PCC (protein catalyzed capture) agent technology is a breakthrough process that produces synthetic peptide molecules capable of binding interactions that are equivalent or superior to molecular antibodies. Current systems employ antibody-based biological tools that are used to capture proteins and enable highly sensitive detection. The joint research and development project will explore the use of PCCs to specifically interact with proteins.
Dr. Doug Fisher, to Speak at Life Sciences Summit
October 29, 2014 | New York, NY | www.lifesciencessummit.org
BioCentury | 31 March 2014 | Emily Cukier-Meisner
“We’ve been able to create a completely synthetic approach to building binding
molecules,” said Albert Luderer, CEO
CULVER CITY, CA — (December 10, 2013) — Indi Molecular, which pioneered a synthetic replacement for antibodies, today announced that it has raised an additional $300,000 from a new investor, Asset Management Ventures. With this investment, the company has expanded its seed round to a total of $1.8 million. The round was led by InterWest Partners and joined by several angel investors. The funds are being used to further develop PCC (protein catalyzed capture) agent technology: a breakthrough process that produces synthetic peptide molecules capable of binding interactions that are equivalent or superior to molecular antibodies. The company also announced that it has published three new papers in recent weeks, appearing in Angewandte Chemie, PLOS One and ACS Nano. All three papers were written in collaboration with researchers at the California Institute of Technology (Caltech), with the goal of furthering the development of PCC technology.
Read MoreSeptember 20, 2013 – Indi Molecular, which pioneered a synthetic replacement for antibodies, today announced that it has raised a $1.5 million seed round led by InterWest Partners and joined by several angel investors. The funds will be used to further develop PCC (protein catalyzed capture) agent technology: a breakthrough process that produces synthetic peptide molecules capable of binding interactions that are equivalent or superior to molecular antibodies. PCCs have several advantages over antibodies, including lower cost, faster development and greater specificity. They are being developed as a replacement for antibodies in in vivo imaging, therapeutics, in vitro diagnostics and biological tools. Indi Molecular, previously an operating division of Integrated Diagnostics (Indi), will now operate as an independent company, while maintaining close ties with its parent company.
Read MorePuget Sound Business Journal | 4 January 2013 |
Patti Payne “Dr. Leroy ‘Lee’ Hood, co-founder and president of the Seattle-based Institute for Systems Biology, has been chosen to receive the highest award bestowed upon scientists by the United States government: the National Medal of Science.” Full Article [subscription required]
Press Release | 13 June 2012
SEATTLE – Integrated Diagnostics (InDi®), an emerging leader in molecular diagnostics, today announced that the company has launched a new operating division, InDi Imaging™, that is creating a new generation of PET imaging probes using the company’s innovative protein catalyzed capture (PCC) agent technology. PCCs, initially developed for in vitro molecular diagnostics, will be employed as rationally designed, in vivo diagnostic imaging probes that mimic the properties of antibodies and biologics in PET molecular imaging, with the benefit of being chemically stable, synthetic small-molecules.
Read MoreXconomy | 13 June 2012 |
Luke Timmerman “This is like going from black and white with no sound to Technicolor and surround sound. It’s big.” Dr. Albert A Luderer, CEO, Integrated Diagnostics.